Mersana Therapeutics Inc MRSN

NAS: MRSN | ISIN: US59045L1061 29/04/2024

3,160 USD (+7,48%)

(+7,48%) 29/04/2024

Toon enkel gratis nieuws

15 maart 2021 · Mersana Therapeutics Announces Publication of Two Manuscripts Detailing Preclinical Studies of the Dolaflexin Platform and Upifitamab Rilsodotin (XMT-1536) in AACR Journal Molecular Cancer Therapeutics · Persbericht

10 maart 2021 · Mersana Therapeutics to Present Three Posters at Upcoming Virtual 2021 American Association for Cancer Research Annual Meeting · Persbericht

26 februari 2021 · Mersana Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update · Persbericht

19 februari 2021 · Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Year End 2020 Financial Results and Business Updates · Persbericht

17 februari 2021 · Mersana Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference · Persbericht

22 januari 2021 · Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

19 januari 2021 · Carla Poulson Joins Mersana Therapeutics as Chief Human Resources Officer · Persbericht

6 januari 2021 · Mersana Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference · Persbericht

5 januari 2021 · Mersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated Milestones · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe